Biodiversity Law Reform Spurs Innovation, But Patent Backlog Remains
Executive Summary
Brazil's new biodiversity research law is viewed as a step toward fostering biological innovation, but patent backlogs of 14 years still prove to be a major deterrent to conducting R&D in the country.
You may also be interested in...
Brazil Patent Agreement Hopes To Increase Flow Of Generics To Market
Joint ordinance signed by Anvisa and INPI hopes to resolve a 16-year impasse between the two agencies and bring predictability to patent application process; Anvisa will be relegated to analyzing public health matters, while INPI will make final patentability determinations.
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.